IV finafloxacin: Completed Phase II enrollment

MerLion completed enrollment in a double-blind, double-dummy, European Phase II trial comparing 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in up to 258 patients. Both finafloxacin formulations have completed Phase IIa trials to treat uncomplicated UTI and Helicobacter pylori infection. Both formulations also have Qualified Infectious Disease Product (QIDP) and Fast Track designations in the U.S. to treat complicated intra-abdominal infections (cIAI), acute bacterial skin and skin structure infections (ABSSSI) and cUTI, including pyelonephritis. ...